Loading
NASDAQHealthcareBiotechnology
Latest quote
$44.41
+$0.04 · +0.09%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Latest quote
$44.41
+$0.04 · +0.09%
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI26.42M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF9.69M0.01%93.7B USD0.05%$242.66+0.14%
Schwab U.S. Small-Cap ETFSCHA3.74M0.02%22.56B USD0.03%$34.55+1.01%
T. Rowe Price Small-Mid Cap ETFTMSL1.65M0.05%2.97B USD0.55%$42.78+0.26%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.56M0.10%1.5B USD0.43%$36.48+0.63%
Schwab U.S. Broad Market ETFSCHB530.23K0.00%44.48B USD0.03%$29.73-0.30%
Vanguard Russell 2000 ETFVTWO338.37K0.00%17.4B USD0.06%$119.62+0.25%
Fidelity MSCI Health Care Index ETFFHLC322.92K0.01%3.29B USD0.08%$83.14-1.02%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAT. Rowe Price Small-Mid Cap ETFTMSLFidelity Fundamental Small-Mid Cap ETFFFSMSchwab U.S. Broad Market ETFSCHBVanguard Russell 2000 ETFVTWOFidelity MSCI Health Care Index ETFFHLCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
